---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Access and distribution"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Access and distribution. Topics: Vertex-sponsored no-cost APOL1 genetic testing: Labcorp program, Vertex-sponsored no-cost APOL1 genetic testing: Natera Renasight program, Vertex-sponsored no-cost APOL1 genetic testing: Arkana Laboratories program, Vertex-sponsored genotyping study for clinical trial referral, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/access-and-distribution"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Vertex-sponsored no-cost APOL1 genetic testing: Labcorp program

> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”
> “No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “This test is sponsored by Vertex and should only be ordered on eligible patients. Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “This program is subject to change or discontinuation without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.1.2.11-2"></a>

### Vertex-sponsored no-cost APOL1 genetic testing: Natera Renasight program

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible”
> “patients of African ancestry diagnosed with chronic kidney disease”
> “The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals Incorporated.”
> “Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.1.2.11-3"></a>

### Vertex-sponsored no-cost APOL1 genetic testing: Arkana Laboratories program

> “Vertex Pharmaceuticals is sponsoring the No Cost to Patient APOL1 Genotyping Program”
> “Vertex Pharmaceuticals will cover the cost of genetic counseling for eligible”
> “Metis Genetics is working with Arkana Laboratories and Vertex Pharmaceuticals to provide pre-test genetic counseling to eligible”
> “Absence of diabetes mellitus”
> “Not currently on dialysis and no history of kidney transplant”

Source: [Arkana Laboratories](https://www.arkanalabs.com/services/apol1/no-cost-to-patient-apol1-testing-patient/)

<a id="topic-2.1.2.11-4"></a>

### Vertex-sponsored genotyping study for clinical trial referral

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR ≥0.5 g/g. One blood sample is collected to verify APOL1 genotype by polymerase chain reaction to describe the genetic prevalence of AMKD and inform eligibility for clinical trials.”
> “The genotyping study interim analysis included 2866 participants of whom 674 (23.5%) have 2 APOL1 variants; 164 of the 674 (24.3%) participants are from Europe.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-2.1.2.11-5"></a>

### Genotype assay required for trial eligibility

> “Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.11-6"></a>

### Companion diagnostic

No evidence found.

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or distribution network

No evidence found.

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
